Hillhurst Biopharmaceuticals

This company develops liquid therapeutic gases for oral delivery, primarily focused on treating sickle cell disease. Their platform delivers low-dose carbon monoxide to manage acute pain and aid in transplant surgery, offering precise dosing without inhalation risks.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Many therapeutic gases with the potential to treat a wide range of diseases are limited by the challenges of inhaled delivery, including inaccurate dosing, safety concerns, and patient compliance issues. Current methods of delivering these gases are often intrusive and unsuitable for convenient at-home administration.

Solution

Hillhurst Bio is developing a novel approach to therapeutic gas delivery through its proprietary Gas in Liquid Advanced Stability System (GLASS™) platform. This technology enables the creation of liquid drug products containing precise concentrations of therapeutic gases for oral administration. By converting inhaled therapeutics into liquid form, Hillhurst Bio aims to provide safer, more convenient, and more accurate dosing, suitable for at-home use. The GLASS™ platform facilitates the gastrointestinal uptake of these agents, expanding the clinical applications of this important class of medication. The company's pipeline includes liquid therapeutic candidates targeting sickle cell disease, Parkinson’s disease, acute pain, diabetic retinopathy, and the prevention of organ damage during transplants and cancer treatment.

Target Audience

Hillhurst Bio's primary target audience includes patients suffering from sickle cell disease, Parkinson’s disease, acute pain, and diabetic retinopathy, as well as clinicians seeking safer and more effective methods for delivering therapeutic gases.

Features

GLASS™ technology platform enables liquid delivery of therapeutic gases, overcoming limitations of inhaled methods.
Precise dosing control, ensuring accurate and consistent delivery of therapeutic agents.
Oral administration route for improved patient convenience and compliance.
HBI-002: Oral low-dose carbon monoxide therapeutic candidate, currently in Phase 2a clinical trials for sickle cell disease and Phase 2a study for Parkinson's disease.
HBI-201: Oral nitrous oxide therapeutic candidate for acute pain management, in preclinical development.
Investigational intravenous dosage form of low dose medical CO (HBI-137) for intraoperative use during kidney transplant surgery.
Potential applications in hematologic, neurodegenerative, cardiovascular, immune, and oncology indications.